The Centers for Medicare & Medicaid Services (CMS) provides a list of National Drug Codes (NDC) associated with selected drugs under the Medicare Drug Price Negotiation Program. These codes represent the NDCs for which a negotiated maximum fair price applies according to CMS guidance.
The file includes the single negotiated price for a 30-day equivalent supply of each selected drug, including prices for NDC-9 per unit and NDC-11 per package. CMS updates the file annually to show inflation-adjusted negotiated prices for selected drugs.
Additional updates are made on a recurring basis to account for new NDC-11s, changes to the application of negotiated prices, or when a drug is no longer selected. CMS publishes these files in both .xlsx and .csv formats.
For the third cycle of negotiations, CMS announced on March 13, 2026, that drug companies manufacturing 15 drugs payable under Medicare Part B and/or covered under Medicare Part D have chosen to participate. One drug selected for renegotiation in this cycle also continues to participate. Negotiations for this cycle occur in 2026, with negotiated prices becoming effective in 2028.
Maximum Fair Price (MFP) explanations are available for drugs from previous negotiation cycles. These explanations detail the data used by CMS to determine offers and consider counteroffers, including details on negotiation meetings and the exchange of offers. To protect proprietary information, these explanations include redactions consistent with CMS confidentiality policies.
Drug manufacturers and other interested parties may review the Medicare Drug Price Negotiation Program Agreement and its instructions. The agreement is executed within the CMS Health Plan Management System (HPMS).
